Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) have been given an average rating of “Hold” by the thirteen brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $21.00.
Several equities analysts recently commented on AMRX shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 target price on shares of Amneal Pharmaceuticals in a report on Thursday, February 28th. Zacks Investment Research lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. ValuEngine lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. Leerink Swann reaffirmed an “outperform” rating and set a $19.00 target price (down previously from $25.00) on shares of Amneal Pharmaceuticals in a report on Thursday, January 3rd. Finally, Morgan Stanley lowered shares of Amneal Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $24.00 to $18.00 in a report on Friday, December 14th.
In other Amneal Pharmaceuticals news, Director Peter R. Terreri sold 23,345 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $12.39, for a total transaction of $289,244.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul Bisaro purchased 17,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were purchased at an average cost of $11.97 per share, with a total value of $203,490.00. The disclosure for this purchase can be found here. Corporate insiders own 3.20% of the company’s stock.
Shares of NYSE:AMRX opened at $14.17 on Friday. The firm has a market capitalization of $4.25 billion, a PE ratio of 14.92, a P/E/G ratio of 0.65 and a beta of 1.37. Amneal Pharmaceuticals has a one year low of $11.63 and a one year high of $24.48. The company has a debt-to-equity ratio of 2.98, a quick ratio of 1.50 and a current ratio of 2.32.
Amneal Pharmaceuticals (NYSE:AMRX) last released its earnings results on Thursday, February 28th. The company reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.06. Amneal Pharmaceuticals had a negative net margin of 9.92% and a positive return on equity of 16.46%. The company had revenue of $497.53 million for the quarter, compared to analyst estimates of $478.06 million. Research analysts expect that Amneal Pharmaceuticals will post 0.98 EPS for the current fiscal year.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: How Do Investors Open a Backdoor Roth IRA?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.